[恶性滋养细胞疾病的分期：一个困境]
[Staging of malignant trophoblast diseases: a dilemma].
作者信息
Köchli O R
机构信息
Universitätsfrauenklinik Zürich, Schweiz.
出版信息
Gynakol Geburtshilfliche Rundsch. 1994;34(1):3-6. doi: 10.1159/000272320.
In the past, three different staging systems have been used for trophoblastic disease: The WHO scoring system, the NIH classification and the FIGO staging system. The NIH classification has been preferred by most oncologists in the United States of America and is currently still first choice. The Federation of Gynecology and Obstetrics (FIGO) published a new staging system in 1992 which includes both prognostic factors and the anatomic spread of the disease. Here we wish to present and evaluate these staging systems.
过去，三种不同的分期系统被用于滋养细胞疾病：世界卫生组织（WHO）评分系统、美国国立卫生研究院（NIH）分类系统和国际妇产科联盟（FIGO）分期系统。美国的大多数肿瘤学家更倾向于NIH分类系统，目前它仍是首选。国际妇产科联盟（FIGO）于1992年公布了一种新的分期系统，该系统既包括预后因素，也包括疾病的解剖学扩散情况。在此，我们希望介绍并评估这些分期系统。
Zotero 插件